Invion Ltd. (AU:IVX) has released an update.
Invion Ltd. reports a significant reduction in operating expenses following one-off payments related to its upcoming Phase I/II skin cancer clinical trial and announces a new collaboration agreement with South Korean company Dr.inB to fund development of Photosoft technology for HPV. The company also revealed promising in vivo study results showing an 80% control of tumours using their INV043 in combination with standard immunotherapy. Despite a delay in ethics application processing, Invion anticipates starting patient recruitment for its skin cancer trial in the near future.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
